1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 44

    Lung biomarkers of harm/effect for tobacco regulatory research: opportunities and challenges – a literature review

    MAKENA P.(1); EDMISTON J.(2); BEATTIE E.(3); MASON E.(4); McEWAN M.(5); PRASAD K.(5)
    (1) RAI Services Company, Winston-Salem, NC, U.S.A.; (2) Altria Client Services LLC, Richmond, VA, U.S.A.; (3) Cliantha Research Limited, Canada; (4) Imperial Brands PLC, Bristol, U.K.; (5) British American Tobacco (Investments) Limited, Southampton, U.K.
    Biomarkers of potential harm (BoPH) are indicators of biological perturbations in response to smoking, which may contribute to smoking-related disease. In this review, a project of the CORESTA Biomarkers Sub-Group, we critically assessed the...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 32

    Enumeration of TBNK cells: A case for a bioanalytical assay to support clinical studies for the development of modified risk tobacco products

    NEWLAND K.; MILLER P.; FARMEN R.
    Celerion, Inc., Lincoln, NE, U.S.A.
    Smoking has been reported to lessen the body’s immune response making it more susceptible to infections. Chronic cigarette smoke exposure causes imbalance in immune homeostasis affecting the circulating immune cells. Peripheral blood lymphocytes are...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 33

    Quantitative risk assessment (QRA) indicates reduced risk potential for carcinogenic and non-carcinogenic effects of the aerosol of the next generation products (NGPs) compared to reference cigarettes

    AYALA-FIERRO F.(1); CZEKALA L.(2); SIMMS L.(2); RUDD K.(2); CAVA G.(2); STEVENSON M.(2)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) Imperial Brands PLC, Bristol, U.K.
    In order to understand the potential relative health risks of NGPs compared to cigarettes, we compared the relative risks of aerosols from tobacco-containing and tobacco-free NGPs to the smoke generated from a reference cigarette. Quantitative Risk...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in...
  5. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 17

    A clinical study investigating changes in exposure to cigarette smoke chemicals in U.K. smokers who switch to using a tobacco heating product for a five-day period

    McEWAN M.(1); EBAJEMITO J.K.(1); GALE N.(1); ELDRIDGE A.(1); CAMACHO O.M.(1); MURPHY J.(1); HARDIE G.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, R&D, Southampton, U.K.; (2) Celerion Inc., Lincoln, NE, U.S.A.
    Smoking is a leading cause of numerous diseases, particularly lung cancer, chronic obstructive pulmonary disease and cardiovascular diseases. Consequently, there is a recognized need to provide smokers with alternative nicotine-delivery devices that...
  6. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 59

    An inter-laboratory comparison study focused on the determination of total NNAL in human urine

    NEWLAND K.(1); SCHERER M.(2); HECHT S.S.(3); TROUDE V.(4); PRASAD G.L.(5)
    (1) Celerion Inc., Lincoln, NE, U.S.A.; (2) ABF GmbH, Planegg, Germany; (3) University of Minnesota Cancer Center, Minneapolis, MN, U.S.A.; (4) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (5) RAI Services Company, Winston-Salem, NC, U.S.A.
    In an ongoing effort to fulfil the second objective of the CORESTA Biomarker Sub-Group, periodic inter-laboratory comparison studies have been performed to evaluate the consistency of the quantitation for various harmful or potentially harmful...
  7. TSRC, Tob. Sci. Res. Conf., 2017, 71, abstr. 014

    Analysis of isotopically labeled glycerol to measure exposure from e-cigarettes

    DIBBERN E.M.; KAFONEK C.J.; BROWN G.P.; DZERK A.M.; NACHI R.; NEWLAND K.E.; ISLAM R. (presented by Erika Pfaumiller)
    Celerion, Lincoln, NE, USA
    Electronic cigarettes (ecigs) have become a popular mode of nicotine ingestion. They are often promoted as being less harmful than traditional cigarettes, but research supporting that claim is incomplete. The main chemical components of ecigs are...
  8. TSRC, Tob. Sci. Res. Conf., 2017, 71, abstr. 067

    Development of an analytical method to detect methyl salicylate in human plasma

    MILLER S.(1); NEWLAND K.(2); LIU J.(1); SARKAR M.(1)
    (1) Altria Client Services, Richmond, VA, USA; (2) Celerion, Lincoln, NE, USA
    Wintergreen is used as a common flavor in many moist smokeless tobacco (MST) products and is also widely used as a food flavorant as well as an over-the-counter analgesic to relieve muscle aches. MST products, including wintergreen flavored products,...
  9. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 04

    Reduction of harmful or potentially harmful constituents (HPHCs) following partial or complete substitution of cigarettes with electronic cigarettes in adult smokers

    D’RUIZ C.D.(1); O’CONNELL G.(2); GRAFF D.W.(3)
    (1) Scientific Affairs Consultant, Fontem Ventures, B.V., Greensboro, NC, U.S.A.; (2) Fontem Ventures, B.V., Scientific and Regulatory Affairs, Amsterdam, The Netherlands; (3) Celerion, Lincoln, NE, U.S.A.
    Changes in fifteen urine, blood, and exhaled breath biomarkers of exposure (BoE) to harmful and potentially harmful constituents (HPHCs), representing major classes of compounds reported by the FDA to be significant contributors to smoking-associated...